Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Rhea-AI Summary

Skye Bioscience (Nasdaq: SKYE) will report third quarter 2025 financial results and host a business update call on November 10, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.

The company will issue its earnings press release and financial tables after market close on November 10, 2025. A live webcast and investor presentation will be available on the Skye Investor Relations website, with a replay posted after the call.

Skye will also present at the Stifel 2025 Healthcare Conference in New York on November 13, 2025 from 4:40–5:10 PM and will be available for one‑on‑one meetings.

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.

The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website.

Skye will also be presenting at the Stifel 2025 Healthcare Conference in New York on Thursday, November 13 at 4:40-5:10 PM and will be available for 1x1 meetings.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on LinkedIn.

CONTACTS

Investor Relations
ir@skyebioscience.com
(858) 410-0266

LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306

Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889

FAQ

When will Skye Bioscience (SKYE) announce Q3 2025 results and hold the earnings call?

Skye will release Q3 2025 results and hold the call on November 10, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.

Where can investors access the Skye Bioscience (SKYE) live webcast and earnings materials?

The live webcast, press release, financial tables, and investor presentation will be on the Skye Investor Relations website.

When will Skye Bioscience (SKYE) issue its Q3 2025 press release?

The company will issue its financial results and business update press release after the market closes on November 10, 2025.

Will there be a replay of the Skye Bioscience (SKYE) Q3 2025 earnings call?

Yes. A replay will be available on the Skye Investor Relations website after the call.

When and where will Skye Bioscience (SKYE) present at the Stifel 2025 Healthcare Conference?

Skye will present in New York on November 13, 2025 from 4:40–5:10 PM and will be available for 1x1 meetings.

What should investors do before the scheduled Skye Bioscience (SKYE) earnings call start time?

Investors are asked to join 5–10 minutes early to ensure timely connection to the webcast and call.